Alternate dosing schedules for cancer chemopreventive agents

Matteo Lazzeroni, Andrea DeCensi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Pharmacologic interventions for cancer risk reduction involve the chronic administration of synthetic or natural agents to reduce or delay the occurrence of malignancy. Despite the strong evidence for a favorable risk-benefit ratio for a number of agents in several common malignancies such as breast and prostate cancer, the public's attitude toward cancer chemoprevention remains ambivalent, with the issue of toxicity associated with drugs being perceived as the main barrier to widespread use of preventive therapy by high-risk subjects. Among the strategies to overcome such obstacles to preventive therapies, two novel and potentially safer modes of administering agents are discussed in this paper. The first strategy is to lower the dose of drugs that are in common use in the adjuvant setting based on the notion that prevention of cancer cells from developing should require a lower dose than eradicating established tumor cells. A second approach is to adopt an intermittent administration similar to what is used in the chemotherapy setting in an attempt to minimize risks while retaining benefits. This article provides a detailed discussion of the principles and future development of these two approaches in the direction of a precision preventive medicine.

Original languageEnglish
Pages (from-to)116-122
Number of pages7
JournalSeminars in Oncology
Volume43
Issue number1
DOIs
Publication statusPublished - Feb 1 2016

Fingerprint

Appointments and Schedules
Neoplasms
Precision Medicine
Preventive Medicine
Chemoprevention
Risk Reduction Behavior
Pharmaceutical Preparations
Prostatic Neoplasms
Odds Ratio
Breast Neoplasms
Drug Therapy
Therapeutics

Keywords

  • Breast cancer
  • Chemoprevention
  • Exemestane
  • Tamoxifen

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Alternate dosing schedules for cancer chemopreventive agents. / Lazzeroni, Matteo; DeCensi, Andrea.

In: Seminars in Oncology, Vol. 43, No. 1, 01.02.2016, p. 116-122.

Research output: Contribution to journalArticle

Lazzeroni, Matteo ; DeCensi, Andrea. / Alternate dosing schedules for cancer chemopreventive agents. In: Seminars in Oncology. 2016 ; Vol. 43, No. 1. pp. 116-122.
@article{8c0b8f743457490291e74e86459de35f,
title = "Alternate dosing schedules for cancer chemopreventive agents",
abstract = "Pharmacologic interventions for cancer risk reduction involve the chronic administration of synthetic or natural agents to reduce or delay the occurrence of malignancy. Despite the strong evidence for a favorable risk-benefit ratio for a number of agents in several common malignancies such as breast and prostate cancer, the public's attitude toward cancer chemoprevention remains ambivalent, with the issue of toxicity associated with drugs being perceived as the main barrier to widespread use of preventive therapy by high-risk subjects. Among the strategies to overcome such obstacles to preventive therapies, two novel and potentially safer modes of administering agents are discussed in this paper. The first strategy is to lower the dose of drugs that are in common use in the adjuvant setting based on the notion that prevention of cancer cells from developing should require a lower dose than eradicating established tumor cells. A second approach is to adopt an intermittent administration similar to what is used in the chemotherapy setting in an attempt to minimize risks while retaining benefits. This article provides a detailed discussion of the principles and future development of these two approaches in the direction of a precision preventive medicine.",
keywords = "Breast cancer, Chemoprevention, Exemestane, Tamoxifen",
author = "Matteo Lazzeroni and Andrea DeCensi",
year = "2016",
month = "2",
day = "1",
doi = "10.1053/j.seminoncol.2015.09.014",
language = "English",
volume = "43",
pages = "116--122",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Alternate dosing schedules for cancer chemopreventive agents

AU - Lazzeroni, Matteo

AU - DeCensi, Andrea

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Pharmacologic interventions for cancer risk reduction involve the chronic administration of synthetic or natural agents to reduce or delay the occurrence of malignancy. Despite the strong evidence for a favorable risk-benefit ratio for a number of agents in several common malignancies such as breast and prostate cancer, the public's attitude toward cancer chemoprevention remains ambivalent, with the issue of toxicity associated with drugs being perceived as the main barrier to widespread use of preventive therapy by high-risk subjects. Among the strategies to overcome such obstacles to preventive therapies, two novel and potentially safer modes of administering agents are discussed in this paper. The first strategy is to lower the dose of drugs that are in common use in the adjuvant setting based on the notion that prevention of cancer cells from developing should require a lower dose than eradicating established tumor cells. A second approach is to adopt an intermittent administration similar to what is used in the chemotherapy setting in an attempt to minimize risks while retaining benefits. This article provides a detailed discussion of the principles and future development of these two approaches in the direction of a precision preventive medicine.

AB - Pharmacologic interventions for cancer risk reduction involve the chronic administration of synthetic or natural agents to reduce or delay the occurrence of malignancy. Despite the strong evidence for a favorable risk-benefit ratio for a number of agents in several common malignancies such as breast and prostate cancer, the public's attitude toward cancer chemoprevention remains ambivalent, with the issue of toxicity associated with drugs being perceived as the main barrier to widespread use of preventive therapy by high-risk subjects. Among the strategies to overcome such obstacles to preventive therapies, two novel and potentially safer modes of administering agents are discussed in this paper. The first strategy is to lower the dose of drugs that are in common use in the adjuvant setting based on the notion that prevention of cancer cells from developing should require a lower dose than eradicating established tumor cells. A second approach is to adopt an intermittent administration similar to what is used in the chemotherapy setting in an attempt to minimize risks while retaining benefits. This article provides a detailed discussion of the principles and future development of these two approaches in the direction of a precision preventive medicine.

KW - Breast cancer

KW - Chemoprevention

KW - Exemestane

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=84960440949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960440949&partnerID=8YFLogxK

U2 - 10.1053/j.seminoncol.2015.09.014

DO - 10.1053/j.seminoncol.2015.09.014

M3 - Article

C2 - 26970130

AN - SCOPUS:84960440949

VL - 43

SP - 116

EP - 122

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 1

ER -